See more : Feng Chi Biotech Corp. (6744.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of NGL Fine-Chem Limited (NGLFINE.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NGL Fine-Chem Limited, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- H.I.S. Co., Ltd. (9603.T) Income Statement Analysis – Financial Results
- ERP Soft Systems Limited (ERPSOFT.BO) Income Statement Analysis – Financial Results
- Robertet SA (RBT.PA) Income Statement Analysis – Financial Results
- Royale Home Holdings Limited (1198.HK) Income Statement Analysis – Financial Results
- Sourcenext Corporation (SRNXF) Income Statement Analysis – Financial Results
NGL Fine-Chem Limited (NGLFINE.NS)
About NGL Fine-Chem Limited
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin for animal health applications; and nitazoxanide, atovaquone, and ranolazine for human health applications. The company also provides various intermediate products; and finished dosage forms in granules and tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.39B | 2.78B | 3.13B | 2.55B | 1.49B | 1.51B | 1.11B | 1.00B | 962.93M | 883.28M | 788.68M | 555.69M | 361.08M | 350.41M | 278.23M | 246.30M | 126.42M |
| Cost of Revenue | 2.70B | 1.40B | 1.47B | 1.02B | 643.67M | 626.37M | 458.67M | 380.85M | 408.17M | 416.40M | 403.56M | 287.31M | 187.12M | 301.82M | 231.86M | 115.40M | 56.01M |
| Gross Profit | 686.26M | 1.38B | 1.66B | 1.53B | 845.88M | 881.39M | 650.70M | 620.69M | 554.75M | 466.88M | 385.12M | 268.38M | 173.97M | 48.59M | 46.38M | 130.90M | 70.41M |
| Gross Profit Ratio | 20.26% | 49.54% | 53.01% | 59.87% | 56.79% | 58.46% | 58.65% | 61.97% | 57.61% | 52.86% | 48.83% | 48.30% | 48.18% | 13.87% | 16.67% | 53.15% | 55.70% |
| Research & Development | 77.63M | 53.19M | 42.67M | 32.80M | 37.62M | 14.21M | 7.85M | 9.34M | 8.53M | 24.93M | 17.46M | 9.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 62.09M | 384.92M | 38.43M | 32.56M | 34.02M | 25.79M | 18.27M | 15.47M | 88.07M | 12.50M | 7.01M | 5.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 99.61M | 6.86M | 110.28M | 71.26M | 44.58M | 43.82M | 41.55M | 30.22M | 6.66M | 53.01M | 40.42M | 12.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 161.70M | 391.78M | 148.71M | 103.82M | 78.60M | 69.61M | 59.82M | 45.69M | 94.74M | 65.51M | 136.38M | 86.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 55.30M | 57.18M | 12.53M | 846.16K | 7.80M | 7.31M | 3.54M | 347.09K | 277.76M | 5.93K | 1.10M | 23.14K | 5.89M | 5.24M | 95.15M | 64.91M |
| Operating Expenses | 557.38M | 1.15B | 1.08B | 763.31M | 706.97M | 586.39M | 480.72M | 395.44M | 366.34M | 343.27M | 298.80M | 213.87M | 150.45M | 5.89M | 5.24M | 95.15M | 64.91M |
| Cost & Expenses | 2.97B | 2.55B | 2.55B | 1.79B | 1.35B | 1.21B | 939.39M | 776.29M | 774.51M | 759.67M | 702.37M | 501.17M | 337.57M | 307.71M | 237.10M | 210.55M | 120.92M |
| Interest Income | 5.99M | 3.24M | 1.78M | 1.98M | 2.24M | 1.54M | 1.77M | 1.46M | 1.32M | 978.90K | 710.21K | 673.24K | 492.56K | 713.54K | 623.07K | 346.58K | 0.00 |
| Interest Expense | 18.10M | 11.97M | 15.62M | 18.40M | 22.55M | 22.87M | 15.55M | 7.18M | 11.73M | 12.55M | 12.90M | 11.80M | 9.15M | 5.62M | 2.79M | 4.27M | 3.45M |
| Depreciation & Amortization | 116.42M | 112.91M | 103.69M | 83.34M | 81.12M | 63.00M | 45.61M | 30.79M | 27.22M | 25.97M | 23.20M | 19.33M | 13.53M | 9.33M | 7.76M | 7.62M | 5.92M |
| EBITDA | 678.69M | 404.87M | 788.78M | 881.27M | 228.10M | 361.54M | 241.30M | 268.97M | 221.59M | 170.06M | 106.12M | 75.58M | 38.31M | 53.47M | 49.91M | 43.36M | 11.42M |
| EBITDA Ratio | 20.04% | 14.33% | 25.10% | 34.20% | 16.57% | 25.97% | 21.14% | 25.80% | 22.60% | 16.75% | 13.99% | 13.63% | 10.61% | 15.25% | 17.94% | 17.61% | 9.03% |
| Operating Income | 416.27M | 230.29M | 574.76M | 759.62M | 135.20M | 295.00M | 169.98M | 225.25M | 188.41M | 123.61M | 86.31M | 54.51M | 23.51M | 42.70M | 41.14M | 35.75M | 5.50M |
| Operating Income Ratio | 12.29% | 8.28% | 18.37% | 29.79% | 9.08% | 19.57% | 15.32% | 22.49% | 19.57% | 13.99% | 10.94% | 9.81% | 6.51% | 12.19% | 14.79% | 14.51% | 4.35% |
| Total Other Income/Expenses | 127.90M | -564.68M | -546.06M | -379.13M | -18.18M | -19.34M | 8.05M | 4.18M | -13.68M | 7.93M | -22.15M | -10.07M | -7.88M | -4.21M | -1.78M | -4.27M | -3.45M |
| Income Before Tax | 544.17M | 273.62M | 665.96M | 775.90M | 120.72M | 275.67M | 178.03M | 220.41M | 178.68M | 128.59M | 67.09M | 44.44M | 15.63M | 38.49M | 39.36M | 31.48M | 2.05M |
| Income Before Tax Ratio | 16.07% | 9.84% | 21.29% | 30.43% | 8.10% | 18.28% | 16.05% | 22.01% | 18.56% | 14.56% | 8.51% | 8.00% | 4.33% | 10.98% | 14.15% | 12.78% | 1.62% |
| Income Tax Expense | 131.00M | 68.66M | 166.99M | 208.71M | 37.37M | 74.40M | 52.10M | 78.02M | 64.70M | 45.29M | 21.81M | 15.35M | 5.16M | 14.33M | 12.31M | 11.88M | 439.00K |
| Net Income | 413.17M | 204.96M | 498.97M | 567.19M | 83.35M | 201.27M | 125.93M | 142.39M | 113.98M | 83.30M | 45.28M | 29.09M | 10.47M | 24.16M | 27.04M | 16.83M | 1.58M |
| Net Income Ratio | 12.20% | 7.37% | 15.95% | 22.24% | 5.60% | 13.35% | 11.35% | 14.22% | 11.84% | 9.43% | 5.74% | 5.24% | 2.90% | 6.89% | 9.72% | 6.83% | 1.25% |
| EPS | 66.88 | 33.18 | 80.77 | 91.81 | 13.49 | 32.58 | 20.38 | 24.09 | 18.45 | 13.48 | 7.33 | 4.71 | 1.69 | 3.90 | 4.38 | 3.17 | 0.26 |
| EPS Diluted | 66.88 | 33.18 | 80.77 | 91.81 | 13.49 | 32.58 | 20.38 | 24.09 | 18.45 | 13.48 | 7.33 | 4.71 | 1.69 | 3.90 | 4.38 | 3.17 | 0.26 |
| Weighted Avg Shares Out | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.06M |
| Weighted Avg Shares Out (Dil) | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.18M | 6.06M |
Source: https://incomestatements.info
Category: Stock Reports